Aster DM Healthcare Reports Strong Financial Performance in Q2 FY25.

Oct 24 2024 09:49 AM IST
share
Share Via
Aster DM Healthcare, a leading healthcare company, has reported positive financial results for the quarter ending September 2024. The company has shown significant growth in PBT and PAT, indicating a strong trend in profitability. However, there are areas for improvement, such as a decline in net sales and operating cash flow.

Aster DM Healthcare, a leading hospital and healthcare services company, has recently announced its financial results for the quarter ending September 2024. The company has shown positive growth in its financial performance, with a score of 8 out of 10, compared to 5 in the previous quarter.

One of the key highlights of the financial results is the significant growth in Profit Before Tax (PBT) and Profit After Tax (PAT). PBT has grown by 201.81% year on year, while PAT has seen a growth of 306.0% year on year. This indicates a strong and positive trend in the company’s near-term profitability.


Another positive aspect of the financial results is the company’s ability to manage interest payments, with the Operating Profit to Interest ratio being the highest in the last five quarters at 6.98 times. This shows that the company is effectively managing its interest payments and is in a good financial position.


However, there are some areas that need improvement, as seen in the decline in Net Sales by -67.24% year on year. This could be due to various factors such as the ongoing pandemic and its impact on the healthcare industry. Additionally, the company’s Operating Cash Flow has also decreased, with the lowest figure in the last three years. This indicates a decline in the company’s cash revenues from business operations.


Overall, Aster DM Healthcare has shown a positive financial performance in the quarter ending September 2024. With a score of 8 out of 10 and strong growth in PBT and PAT, the company is on a positive trajectory. However, there are some areas that need improvement, and it will be interesting to see how the company addresses these challenges in the coming quarters.


{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News